Theriva Biologics Shares Are Trading Higher After the Company Announced It Will Present Preclinical Data for the Potential Synergy of VCN-01 and First-line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics宣布将在美国细胞与基因疗法学会第27届年会上公布有关 VCN-01 和一线胰腺癌化疗方案的潜在协同作用的临床前数据，此后，该公司股价走高